These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 8676354)

  • 1. Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives: potent and selective A(2A) adenosine antagonists.
    Baraldi PG; Cacciari B; Spalluto G; Pineda de las Infantas y Villatoro MJ; Zocchi C; Dionisotti S; Ongini E
    J Med Chem; 1996 Mar; 39(5):1164-71. PubMed ID: 8676354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The non-xanthine heterocyclic compound SCH 58261 is a new potent and selective A2a adenosine receptor antagonist.
    Zocchi C; Ongini E; Conti A; Monopoli A; Negretti A; Baraldi PG; Dionisotti S
    J Pharmacol Exp Ther; 1996 Feb; 276(2):398-404. PubMed ID: 8632302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists.
    Baraldi PG; Fruttarolo F; Tabrizi MA; Preti D; Romagnoli R; El-Kashef H; Moorman A; Varani K; Gessi S; Merighi S; Borea PA
    J Med Chem; 2003 Mar; 46(7):1229-41. PubMed ID: 12646033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and biological evaluation of a second generation of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as potent and selective A2A adenosine receptor antagonists.
    Baraldi PG; Cacciari B; Spalluto G; Bergonzoni M; Dionisotti S; Ongini E; Varani K; Borea PA
    J Med Chem; 1998 Jun; 41(12):2126-33. PubMed ID: 9622554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chiral pyrrolo[2,3-d]pyrimidine and pyrimido[4,5-b]indole derivatives: structure-activity relationships of potent, highly stereoselective A1-adenosine receptor antagonists.
    Müller CE; Geis U; Grahner B; Lanzner W; Eger K
    J Med Chem; 1996 Jun; 39(13):2482-91. PubMed ID: 8691445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor antagonists. Influence of the N5 substituent on the affinity at the human A 3 and A 2B adenosine receptor subtypes: a molecular modeling investigation.
    Pastorin G; Da Ros T; Spalluto G; Deflorian F; Moro S; Cacciari B; Baraldi PG; Gessi S; Varani K; Borea PA
    J Med Chem; 2003 Sep; 46(20):4287-96. PubMed ID: 13678407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and structure-activity relationship of pyrazolo[3,4-d]pyrimidines: potent and selective adenosine A1 receptor antagonists.
    Poulsen SA; Quinn RJ
    J Med Chem; 1996 Oct; 39(21):4156-61. PubMed ID: 8863792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-alkenyl and 2-alkyl derivatives of adenosine and adenosine-5'-N-ethyluronamide: different affinity and selectivity of E- and Z-diastereomers at A2A adenosine receptors.
    Vittori S; Camaioni E; Di Francesco E; Volpini R; Monopoli A; Dionisotti S; Ongini E; Cristalli G
    J Med Chem; 1996 Oct; 39(21):4211-7. PubMed ID: 8863798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a new series of pyrazolo-triazolo-pyrimidines as potent and highly selective hA(3) adenosine receptors antagonists: new insights into structure-affinity relationship and receptor-antagonist recognition.
    Cheong SL; Dolzhenko A; Kachler S; Paoletta S; Federico S; Cacciari B; Dolzhenko A; Klotz KN; Moro S; Spalluto G; Pastorin G
    J Med Chem; 2010 Apr; 53(8):3361-75. PubMed ID: 20307065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyrrolo- and pyrazolo-[3,4-e][1,2,4]triazolo[1,5-c]pyrimidines as adenosine receptor antagonists.
    Baraldi PG; Saponaro G; Aghazadeh Tabrizi M; Baraldi S; Romagnoli R; Moorman AR; Varani K; Borea PA; Preti D
    Bioorg Med Chem; 2012 Jan; 20(2):1046-59. PubMed ID: 22204739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel 3-aralkyl-7-(amino-substituted)-1,2,3-triazolo[4,5-d]pyrimidines with high affinity toward A1 adenosine receptors.
    Betti L; Biagi G; Giannaccini G; Giorgi I; Livi O; Lucacchini A; Manera C; Scartoni V
    J Med Chem; 1998 Feb; 41(5):668-73. PubMed ID: 9513594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists.
    Baraldi PG; Tabrizi MA; Preti D; Bovero A; Romagnoli R; Fruttarolo F; Zaid NA; Moorman AR; Varani K; Gessi S; Merighi S; Borea PA
    J Med Chem; 2004 Mar; 47(6):1434-47. PubMed ID: 14998332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [(3)H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors.
    Varani K; Merighi S; Gessi S; Klotz KN; Leung E; Baraldi PG; Cacciari B; Romagnoli R; Spalluto G; Borea PA
    Mol Pharmacol; 2000 May; 57(5):968-75. PubMed ID: 10779381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and pharmacology of pyrido[2,3-d]pyrimidinediones bearing polar substituents as adenosine receptor antagonists.
    Bulicz J; Bertarelli DC; Baumert D; Fülle F; Müller CE; Heber D
    Bioorg Med Chem; 2006 Apr; 14(8):2837-49. PubMed ID: 16377196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of human A2A adenosine receptors with the antagonist radioligand [3H]-SCH 58261.
    Dionisotti S; Ongini E; Zocchi C; Kull B; Arslan G; Fredholm BB
    Br J Pharmacol; 1997 Jun; 121(3):353-60. PubMed ID: 9179373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and structure-activity relationships of 3,7-dimethyl-1-propargylxanthine derivatives, A2A-selective adenosine receptor antagonists.
    Müller CE; Geis U; Hipp J; Schobert U; Frobenius W; Pawłowski M; Suzuki F; Sandoval-Ramírez J
    J Med Chem; 1997 Dec; 40(26):4396-405. PubMed ID: 9435909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological activity of new potential agonists for the human adenosine A2A receptor.
    Bosch MP; Campos F; Niubó I; Rosell G; Díaz JL; Brea J; Loza MI; Guerrero A
    J Med Chem; 2004 Jul; 47(16):4041-53. PubMed ID: 15267242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining selectivity and affinity predictions using an integrated Support Vector Machine (SVM) approach: An alternative tool to discriminate between the human adenosine A(2A) and A(3) receptor pyrazolo-triazolo-pyrimidine antagonists binding sites.
    Michielan L; Bolcato C; Federico S; Cacciari B; Bacilieri M; Klotz KN; Kachler S; Pastorin G; Cardin R; Sperduti A; Spalluto G; Moro S
    Bioorg Med Chem; 2009 Jul; 17(14):5259-74. PubMed ID: 19501513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Labeling of A2A adenosine receptors in human platelets by use of the new nonxanthine antagonist radioligand [3H]SCH 58261.
    Dionisotti S; Ferrara S; Molta C; Zocchi C; Ongini E
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1209-14. PubMed ID: 8819504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amino-substituted 1,8-naphthyridines and pyrido[2,3-d]pyrimidines: new compounds with affinity for A1- and A2-adenosine receptors.
    Müller CE; Grahner B; Heber D
    Pharmazie; 1994 Dec; 49(12):878-80. PubMed ID: 7838877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.